The current P/E ratio for Catalyst Pharmaceuticals stock as of Nov 22, 2024 is 17.18. This is calculated based on the current EPS of $1.25 and the stock price of $21.48 per share. The PE ratio has decreased by 27% from the past four quarters average of 23.5.
The average historical PE ratio of Catalyst Pharmaceuticals for the last six years is 17.37. The current price-to-earnings ratio of 17.18 is in line with the historical average. In the past six years, CPRX's PE ratio reached its highest point in the Sep 2019 quarter at 59, when the stock price was $5.31 and the EPS was $0.09. The lowest point was recorded in the Sep 2020 quarter, when it reached 4.3 with a price of $2.97 and an EPS of $0.69.
Maximum annual increase: 284.05% in 2021
Maximum annual decrease: -61.65% in 2020
Year | PE ratio | Change |
---|---|---|
2023 | 25.09 | 7.91% |
2022 | 23.25 | 30.47% |
2021 | 17.82 | 284.05% |
2020 | 4.64 | -61.65% |
2019 | 12.1 | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
The current PE ratio of CPRX is above its 5-year historical average, but it is lower than the 3 and 10-year averages.
When compared to its peer stocks JNJ and ABT, CPRX's PE ratio is lower. Catalyst Pharmaceuticals is presently trading at a lower PE ratio (17.18) than its peer group average of 41.24.
Stock name | PE ratio | Market cap |
---|---|---|
CPRX Catalyst Pharmaceuticals Inc | 17.12 | $2.55B |
JNJ Johnson & Johnson | 25.85 | $375.29B |
PFE Pfizer Inc | 34.2 | $147.29B |
ABT Abbott Laboratories | 35.78 | $204.8B |
BMRN Biomarin Pharmaceutical Inc | 38.48 | $12.47B |
SRPT Sarepta Therapeutics Inc | 73.65 | $10.97B |
CPRX stock has a price to earnings ratio of 17.18 as of Nov 22, 2024.
As an average over the last 3 years, CPRX stock has a PE ratio of 19.68.
As an average over the last 5 years, CPRX stock has a PE ratio of 15.29.
Over the last six years, the quarterly PE ratio reached a historic high of 59 in the Sep 2019 quarter.
The current price to earnings ratio of CPRX is 1.1% lower than the 6-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Nov 22, 2024), Catalyst Pharmaceuticals's stock price is $21.48. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $1.25. Therefore, Catalyst Pharmaceuticals's price to earnings ratio for today is 17.18. PE RATIO(17.18) = STOCK PRICE($21.48) / TTM EPS($1.25)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.